Playing the Long Game, Partnerships Required For Emerging Infectious Diseases
Bringing drugs and vaccines for emerging infectious diseases to the marketplace requires playing the long game and collaborations if efforts are going to be successful.
You may also be interested in...
Update to 2005 outline of US response to pandemic influenza was due at the end of 2016, but has yet to be released.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Agency wanted to move fast, but is now scrambling to pay for Phases I and II trials.